Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 9/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 4/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17141969 | 0.78 | LMNA (0.41) | USP2LMNAMAPTALDH1A1MAPK1 | |
| SCHEMBL17141999 | 0.76 | USP2 (0.55) | USP2LMNAMAPTALDH1A1MAPK1 | |
| SCHEMBL9963140 | 0.76 | KCNH2 (0.47) | USP2LMNAMAPTALDH1A1MAPK1 | |
| SCHEMBL11932553 | 0.67 | PRKDC (0.43) | LMNAMAPTALDH1A1MAPK1THRB | |
| SCHEMBL17141968 | 0.65 | NEDD4 (0.51) | KMT2A | |
| SCHEMBL17142010 | 0.65 | NEDD4 (0.57) | USP2LMNAMAPTALDH1A1MAPK1 | |
| SCHEMBL11938949 | 0.65 | POLB (0.50) | LMNAPOLB | |
| SCHEMBL21361620 | 0.64 | LMNA (0.57) | USP2LMNAMAPTALDH1A1MAPK1 | |
| SCHEMBL17142028 | 0.64 | NEDD4 (0.53) | USP2LMNAMAPTALDH1A1MAPK1 | |
| SCHEMBL17141957 | 0.64 | DRD4 (0.44) | USP2LMNAALDH1A1NPSR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174678-A1 | NOVEL ANTIVIRAL COMPOUNDS AND METHODS USING SAME | Rhe Trustees of The University of Pennsylvania | 2017-06-22 | — | — | US | claimed |
| EP-3126005-A1 | NOVEL ANTIVIRAL COMPOUNDS AND METHODS USING SAME | The Trustees Of The University Of Pennsylvania (US) | 2017-02-08 | — | — | EP | claimed |
| WO-2015153554-A1 | NOVEL ANTIVIRAL COMPOUNDS AND METHODS USING SAME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-10-08 | — | — | WO | claimed |
| US-10160756-B2 | Antiviral compounds and methods using same | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-12-25 | — | — | US | disclosed |
| US-20170174678-A1 | NOVEL ANTIVIRAL COMPOUNDS AND METHODS USING SAME | Rhe Trustees of The University of Pennsylvania | 2017-06-22 | — | — | US | disclosed |
| US-20170174678-A1 | NOVEL ANTIVIRAL COMPOUNDS AND METHODS USING SAME | Rhe Trustees of The University of Pennsylvania | 2017-06-22 | — | — | US | disclosed |
| US-20170174678-A1 | NOVEL ANTIVIRAL COMPOUNDS AND METHODS USING SAME | Rhe Trustees of The University of Pennsylvania | 2017-06-22 | — | — | US | disclosed |
| EP-3126005-A1 | NOVEL ANTIVIRAL COMPOUNDS AND METHODS USING SAME | The Trustees Of The University Of Pennsylvania (US) | 2017-02-08 | — | — | EP | disclosed |
| WO-2015153554-A1 | NOVEL ANTIVIRAL COMPOUNDS AND METHODS USING SAME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-10-08 | — | — | WO | disclosed |
| WO-2015153554-A1 | NOVEL ANTIVIRAL COMPOUNDS AND METHODS USING SAME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174678-A1 | NOVEL ANTIVIRAL COMPOUNDS AND METHODS USING SAME | ZC3HAV1, MAVS, ZC3HAV1L | USP2 3901/4885LMNA 2215/4885MAPT 4743/4885 |
| US-10160756-B2 | Antiviral compounds and methods using same | ZC3HAV1, MAVS, ZC3HAV1L | USP2 3933/4885LMNA 2151/4885MAPT 4690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.